Pet Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Vaccination, By Mode Of Administration, By Region & Competition, 2021-2031F

The Global Pet Vaccine Market is projected to expand from a valuation of USD 2.14 Billion in 2025 to USD 3.09 Billion by 2031, registering a CAGR of 6.31%. These biological preparations are engineered to trigger immune responses in companion animals, generating antibodies that confer immunity against various viral, bacterial, and parasitic infections. Key growth factors include the increasing incidence of zoonotic risks and a surge in global pet adoption, which underscores the need for regular preventative veterinary attention. Additionally, strict government regulations concerning rabies control, alongside the trend of pet humanization, drive higher adherence to vaccination schedules. For instance, Animal Medicines Australia reported in 2025 that 73% of Australian households possessed a pet, highlighting the strong ownership rates that fuel demand for veterinary biologicals in developed regions.

However, market progress is often hindered by the rising expense of veterinary services, which creates economic obstacles for budget-conscious pet owners. The substantial costs linked to routine wellness check-ups and vaccine administration frequently result in delayed treatments or failure to adhere to annual booster timelines. This financial limitation, combined with logistical difficulties in preserving cold-chain integrity during transport to isolated regions, persists as a major impediment to the consistent expansion of the global pet vaccine sector.

Market Driver

The increasing humanization of companion animals serves as a major engine for market expansion, heavily impacting the demand for preventative health solutions and adherence to immunization plans. As owners increasingly regard their pets as essential family members, they are more disposed to prioritize their health and lifespan, resulting in stricter compliance with vaccination protocols against bacterial and viral dangers. This cultural evolution effectively broadens the potential market for biologicals by ensuring a greater share of the pet population obtains regular care. The scale of this ownership base is significant; UK Pet Food's 'Pet Data Report 2024' from March 2024 noted that the United Kingdom's total pet population stood at 36 million, emphasizing the immense number of animals needing regular veterinary care.

Simultaneously, rising spending on veterinary healthcare supports the market by enabling the uptake of premium and innovative vaccine products. The growing readiness of owners to dedicate substantial funds to medical services helps offset potential cost hurdles, fostering value growth within the industry. According to the American Pet Products Association's 'State of the Industry 2025' report released in March 2025, annual expenditures on veterinary care and product sales in the United States were anticipated to hit $41.4 billion, signaling a strong commitment to animal wellness. This financial dedication is reinforced by active engagement with veterinary experts; Animal Medicines Australia's 'Pets in Australia 2025' report from September 2025 indicated that 89% of dogs and 75% of cats visited a veterinarian in the prior year, illustrating the high compliance levels that secure recurring revenue for manufacturers.

Market Challenge

The escalating cost of veterinary services constitutes a major barrier to the expansion of the global pet vaccine market. As the financial weight of routine animal healthcare increases, budget-conscious owners are frequently compelled to choose urgent medical treatments over preventative actions like vaccination. This economic pressure disrupts the continuity of care necessary for effective immunization regimens, causing a decrease in the total volume of vaccines administered. When wellness exams become too costly, owners often postpone these essential visits, leading to missed chances for veterinarians to provide required annual boosters and sustain immunity levels.

Consequently, this pattern of delayed maintenance leads to a direct contraction in market demand. When owners fail to maintain recommended vaccination schedules, it undermines herd immunity and stalls revenue generation for vaccine producers. Data from the American Veterinary Medical Association in 2025 showed that veterinary service prices rose by 5.7 percent, coinciding with a 3 percent year-over-year drop in patient visits. This link between increasing costs and reduced clinic attendance illustrates how affordability issues significantly hinder the industry's capacity to sustain steady growth rates in both developed and emerging regions.

Market Trends

The commercialization of therapeutic vaccines for chronic conditions is fundamentally transforming the Global Pet Vaccine Market by broadening the focus of immunization from infectious disease prevention to the active management of complex, non-infectious ailments such as oncology. Manufacturers are increasingly utilizing autologous and precision immunotherapy technologies to develop biologicals that prompt a companion animal's immune system to attack tumor-specific antigens. This clinical advancement offers veterinarians effective interventions for terminal conditions that previously had few options. For example, a February 2025 press release from Torigen Pharmaceuticals regarding 'New Hope For Pets In The Fight Against Cancer' reported that dogs with metastatic hemangiosarcoma treated with their targeted autologous cancer vaccine showed a 3.5-fold increase in overall survival compared to those receiving surgery alone, validating the rising reliance on therapeutic biologicals for aging pets.

At the same time, the shift toward recombinant and subunit vaccine platforms is altering the industry's manufacturing landscape as companies move away from conventional live-attenuated techniques to improve safety and production scalability. This trend emphasizes the creation of high-purity antigens and large-molecule biologicals, requiring significant capital investments in bioprocessing infrastructure to guarantee supply chain stability. This strategic move to advanced platform technologies is demonstrated by major industrial commitments; in May 2025, Merck Animal Health announced an investment of $895 million to expand its De Soto, Kansas facility to boost production capacity for large molecule vaccines and biologics. Such expenditures highlight the market's dedication to sophisticated delivery systems that provide enhanced potency and lower risks of adverse reactions in companion animals.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

Report Scope

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Vaccine Market, By Animal Type

• Canine
• Feline
• Equine

Pet Vaccine Market, By Vaccination

• Canine Family
• Feline Family
• Others

Pet Vaccine Market, By Mode Of Administration

• Injectable Vaccines
• Intranasal Vaccines

Pet Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pet Vaccine Market.

Available Customizations:

Global Pet Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).